Affibody molekyler, en ny typ av målsökande proteiner för molekylär imaging. Molekylär design av målsökningsegenskaper för anti-tumör affibody molekyler.
Tidsperiod: 2013-01-01 till 2015-12-31
Budget: 2 100 000 SEK
Radionuclide imaging of molecular targets in vivo is a promising way to increase specificity of cancer treatment. Affibody molecules constitute a new type of affinity proteins, which has been developed by researchers at KTH and evaluated by the applicant´s group as imaging probes. High affinity, small size and high structural stability of affibody molecules make them suitable as targeting agents for radionuclide diagnostics and therapy of malignant tumours. Pre-clinical and clinical studies demonstrated high potential of affibody molecules for nuclear medicine. The goal of this project is to further improve sensitivity of radionuclide imaging using the affibody molecules for radionuclide imaging. This planned to be achieved: 1. by optimising their biodistribution and minimizing uptake in non-specific compartments. An emphasis is on influence of labelling chemistry on biodistribution and imaging properties of affibody molecules. 2. by the use of positron emission tomography as an imaging technique. In the case of success, this would enable to develop tumour-targeting affibody molecules with an improved sensitivity and pre-determined biological properties. The use of a generator-produced Tc-99m or Ga-68 would reduce costs of imaging procedures. The information obtained within this project could be used for radionuclide labelling of other small scaffold affinity proteins for tumour targeting, facilitating the application of these proteins in medicine and biology.